Cytek Biosciences (CTKB) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed Seer (SEER) over the past year, gaining 40.9% versus a loss of 0.5%. Over five years, CTKB leads with a -77.8% price change compared with -93.3% for SEER. Cytek Biosciences is the larger company by market cap ($688.9 million vs $121.5 million), about 5.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | SEER |
|---|---|---|
| Share price | $5.30 | $2.20 |
| Market cap | $688.91M | $121.54M |
| 1-day change | -0.75% | -0.68% |
| YTD return | +5.74% | +20.77% |
| 1-year return | +40.90% | -0.45% |
| 5-year return | -77.81% | -93.30% |
| Forward P/E | 75.71 | — |
| EPS (TTM) | $-0.62 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.21 | $2.41 |
| 52-week low | $3.31 | $1.55 |
| Distance from 52-week high | -14.65% | -8.92% |
| Analyst consensus | none | none |
| Avg. price target upside | +4.91% | +82.23% |
| Average volume | 1.04M | 481.54K |
| Shares outstanding | 129.98M | 55.37M |
| Employees | 682 | 124 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cytek Biosciences is about 5.7 times larger than Seer by market value ($688.91M vs $121.54M).
- CTKB has outperformed SEER by 41.3 percentage points over the past year.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
CTKB vs SEER FAQ
Which is bigger, Cytek Biosciences or Seer?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $688.91M compared with $121.54M for Seer (SEER).
Which stock has performed better over the past year, CTKB or SEER?
CTKB returned +40.90% over the past 12 months, compared with -0.45% for SEER (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and Seer in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.